TY - JOUR
T1 - Temperature-Controlled pNIB/PTX Micelles for Improved Paclitaxel Delivery in Ovarian Cancer Treatment
AU - Kang, Ji Hye
AU - Cho, Young Jae
AU - Hwang, Ji Young
AU - Park, Sang Yu
AU - Choi, Jung Joo
AU - Paik, E. Sun
AU - Kim, Han Sem
AU - Lee, Jeong Won
AU - Shin, Ueon Sang
N1 - Publisher Copyright:
© 2025 American Chemical Society.
PY - 2025/4/14
Y1 - 2025/4/14
N2 - Paclitaxel (PTX) is a widely used anticancer drug for ovarian cancer treatment, but its clinical application is limited by poor water solubility and dose-limiting toxicities. To overcome these challenges, we developed a thermoresponsive, multistep drug delivery system, pNIB/PTX, designed to improve PTX solubility and provide controlled drug release. The pNIB/PTX-3 complex exhibited an initial rapid drug release phase followed by sustained slow release, optimizing both short-term and long-term therapeutic efficacy. At physiological temperatures, the complex demonstrated a precisely controlled drug release mechanism driven by changes in the polymeric micelle structure. In vitro studies showed that pNIB/PTX-3 significantly enhanced therapeutic effects in human ovarian cancer cell lines HeyA8 and SKOV3ip1, compared to PTX alone. In orthotopic ovarian cancer mouse models, a single intraperitoneal injection of pNIB/PTX-3 led to a substantial reduction in tumor size and prolonged survival. This multistep, thermoresponsive delivery system shows strong potential as a promising therapeutic option for dose-dense ovarian cancer treatments, providing improved drug stability, controlled release, and minimized side effects.
AB - Paclitaxel (PTX) is a widely used anticancer drug for ovarian cancer treatment, but its clinical application is limited by poor water solubility and dose-limiting toxicities. To overcome these challenges, we developed a thermoresponsive, multistep drug delivery system, pNIB/PTX, designed to improve PTX solubility and provide controlled drug release. The pNIB/PTX-3 complex exhibited an initial rapid drug release phase followed by sustained slow release, optimizing both short-term and long-term therapeutic efficacy. At physiological temperatures, the complex demonstrated a precisely controlled drug release mechanism driven by changes in the polymeric micelle structure. In vitro studies showed that pNIB/PTX-3 significantly enhanced therapeutic effects in human ovarian cancer cell lines HeyA8 and SKOV3ip1, compared to PTX alone. In orthotopic ovarian cancer mouse models, a single intraperitoneal injection of pNIB/PTX-3 led to a substantial reduction in tumor size and prolonged survival. This multistep, thermoresponsive delivery system shows strong potential as a promising therapeutic option for dose-dense ovarian cancer treatments, providing improved drug stability, controlled release, and minimized side effects.
KW - controlled drug release
KW - ovarian cancer therapy
KW - pNIB/PTX polymeric micelles
KW - thermoresponsive drug delivery
UR - https://www.scopus.com/pages/publications/105000273973
U2 - 10.1021/acsbiomaterials.4c02060
DO - 10.1021/acsbiomaterials.4c02060
M3 - Article
C2 - 40094480
AN - SCOPUS:105000273973
SN - 2373-9878
VL - 11
SP - 2167
EP - 2179
JO - ACS Biomaterials Science and Engineering
JF - ACS Biomaterials Science and Engineering
IS - 4
ER -
